Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Bicara Therapeutics Inc. (NASDAQ: BCAX), a clinical-stage biopharmaceutical company developing the bifunctional antibody ficerafusp alfa for solid tumors. As a public issuer, Bicara submits periodic and current reports that provide detail on its financial position, research and development spending, and key clinical and corporate events.
Among the filings available for review are Form 10-K annual reports and Form 10-Q quarterly reports, which describe operating expenses, including research and development and general and administrative costs, as well as cash, cash equivalents, and investments. These documents give insight into how Bicara funds the pivotal FORTIFI-HN01 trial in recurrent/metastatic head and neck squamous cell carcinoma and its Phase 1/1b expansion cohorts in head and neck cancer and metastatic colorectal cancer.
Form 8-K current reports, such as those referenced in the provided data, furnish press releases on quarterly financial results and business updates. These filings often summarize recent clinical milestones for ficerafusp alfa, including dose-optimization progress, expansion cohort data, and regulatory developments like Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
Investors can also use this page to access exhibits attached to Bicara’s SEC filings, which may include detailed financial statements, risk factor discussions, and other disclosures relevant to evaluating a clinical-stage biotechnology company. Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly identify information on operating expenses, cash runway, clinical trial status, and other factors that influence the outlook for BCAX.
Bicara Therapeutics Inc. reported that its Chief Legal Officer, Lara Meisner, received a grant of stock options on February 2, 2026. The award covers 90,000 options to buy common stock at an exercise price of $16.76 per share.
The options vest in sixteen equal quarterly installments following February 2, 2026, and each vesting event requires Meisner’s continued service with the company. After this grant, she directly holds 90,000 derivative securities in the form of stock options.
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp, who is also a director, reported selling 3,828 shares of common stock on January 22, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025, which is designed to allow insiders to trade on a scheduled basis. The shares were sold at a weighted average price of $18.1024, with individual trade prices ranging from $18.00 to $18.19. Following this transaction, Cohlhepp directly beneficially owns 210,164 shares of Bicara common stock.
Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan reported an option exercise and matching share sale on January 22, 2026. Ivan exercised a stock option for 1,882 shares of common stock at $3.7898 per share, then sold 1,882 common shares at a weighted average price of $18.1522 under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. Following these transactions, Ivan directly holds 145,355 shares of common stock and 65,462 stock options. The option underlying the exercised shares vests in sixteen equal quarterly installments following April 5, 2023, subject to continued service.
BCAX insider Ryan Cohlhepp has filed a Form 144 notice to sell 3,828 shares of the company’s common stock through UBS Financial Services, Inc. on or about January 22, 2026 on the NASDAQ market. The planned sale has an aggregate market value of
The filing also lists prior sales of BCAX common stock by Cohlhepp during the past three months, including 12,500 shares sold on
BCAX insider Ivan Hyep has filed a Form 144 notice to sell 1,882 shares of common stock through UBS Financial Services, Inc., with an aggregate market value of $34,158.30 on NASDAQ around 01/22/2026. These shares were acquired the same day via a cash exercise of stock options from the issuer. The filing notes that 54,781,950 shares of this class were outstanding. Over the past three months, the same seller reported additional BCAX common stock sales totaling several thousand shares, with gross proceeds including $168,491.56, $10,980.75, and $330,093.69.
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp, who also serves as a director, reported a small open-market sale of company stock. On January 15, 2026, he sold 149 shares of Common Stock at a price of $18.02 per share, coded as a sale transaction. After this trade, he beneficially owned 213,992 shares of Bicara Therapeutics Common Stock in direct ownership form. The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that was adopted on February 12, 2025, indicating it was pre-arranged under SEC rules.
BCAX insider Ryan Cohlhepp filed a Rule 144 notice to sell 149 shares of the company’s common stock through UBS Financial Services on or around 01/15/2026, with an aggregate market value of $2,684.98. The filing reports that these shares were acquired on 05/12/2024 by exercising a stock option for cash. The notice indicates total common shares outstanding of 54,781,950, showing this planned sale is very small relative to the company’s share base.
Over the prior three months, Cohlhepp sold additional common shares in three equal blocks of 12,500 shares each on 10/15/2025, 11/21/2025, and 12/15/2025, with reported gross proceeds of $226,942.50, $225,587.50, and $233,547.50, respectively. The signer represents that he does not know of any undisclosed material adverse information about BCAX at the time of this notice.
Bicara Therapeutics Inc. filed a Form 8-K to report that it issued a press release on January 12, 2026 titled “Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook.”
The company states that this press release is furnished as Exhibit 99.1 and incorporated by reference, indicating it contains details on the chosen Phase 3 dose and management’s outlook for 2026.
Bicara Therapeutics Inc. disclosed that its Chief Executive Officer and director exercised stock options and acquired common shares. On 12/16/2025, the reporting person exercised a stock option and acquired 29,500 shares of common stock at an exercise price of $5.4537 per share. After this transaction, the reporting person beneficially owned 339,392 shares of common stock directly.
The exercised option was part of a larger grant of stock options with an exercise price of $5.4537, originally covering shares of common stock and expiring on 12/14/2033. Following the reported transaction, the reporting person held 565,512 stock options directly. The option grant vests in sixteen equal quarterly installments following December 14, 2023, subject to the reporting person’s continued service.
Bicara Therapeutics reported insider transactions by its President and COO, who is also a director. On December 15, 2025, the insider exercised stock options for 8,000 shares of common stock at an exercise price of $3.7898 per share and, in separate trades, sold 8,000 and 4,500 shares of common stock at a weighted average price of $18.6838 per share under a Rule 10b5-1 trading plan adopted on February 12, 2025.
After these transactions, the insider directly owned 189,141 shares of Bicara common stock and held 141,334 stock options. The option covers 8,000 underlying shares in this transaction, carries a $3.7898 exercise price, expires on August 8, 2033, and vests in sixteen equal quarterly installments following August 8, 2023, subject to continued service.